BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer - BioPharm International
BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer BioPharm International
The efficacy of ultrasound-guided treatment of ovarian endometriosis cysts: A meta-analysis.
The purpose of this meta-analysis was to systematically assess the efficacy of ultrasound-guided therapy of ovarian endometriosis cyst (OEC). Several databases were searched to gather published studies on the efficacy …
Social Media Health Information Formats and Endometriosis Treatment-Seeking Intentions: A Randomized Controlled Trial.
BackgroundDespite many women learning about endometriosis on social media, posts about the condition often fail to reflect current evidence. With the content and credibility of online health messages being found …
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times
New perspectives in managing chronic pelvic pain in Endometriosis: the role of GnRH antagonists versus dienogest.
Endometriosis is a chronic, estrogen-dependent inflammatory disease affecting about 10% of reproductive-age women. Chronic pelvic pain is its most disabling symptom, and available therapies often show limited long-term efficacy and …
Linzagolix, with and without add-back therapy, in women with endometriosis-associated pain: results from EDELWEISS 6, a double-blind randomized extension and withdrawal study.
Was the efficacy of linzagolix, observed at 6 months in women with endometriosis-associated pain, maintained when administered for an additional 6 months?